Dow Venture Capital, the corporate venturing unit of US-based Dow Chemical Company, has reinvested in Germany-based healthcare company Noxxon Pharma’s fourth round of funding.
Noxxon raised €33m ($40.8m) in its series D round led by US and Germany-based venture capital firm NGN Capital as a new investor. NGN’s VC and German state-backed peers, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, FCP Op Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt…